Company Culture Research & Development History Honors & Qualifications Corporate Social Responsibility

About Us

Founded in 2010 and listed on the SSE STAR Market in December 2019, Jiangsu Bioperfectus Technologies Co., Ltd. (“BioPerfectus”, stock code: 688399.SH) is a National High-Tech Enterprise recognized in China for its specialized expertise and strong innovation capabilities. The company integrates in vitro diagnostic products, medical testing services, and consumer healthcare solutions.




As a technology pioneer and industry enabler in molecular diagnostics, BioPerfectus has built deep expertise in infectious disease testing and women’s and children’s health. The company has independently developed more than 700 in vitro diagnostic reagents and intelligent automated instruments, establishing a full-industry-chain layout that spans key raw materials, medical laboratory products, and specialized technical services. Its comprehensive, full-stack solutions support diverse application scenarios, including clinical diagnosis, public health prevention and control, and at-home self-testing.




Built on its core multiplex real-time PCR and POCT platforms, BioPerfectus is accelerating the development and clinical translation of advanced technologies such as digital PCR, mass spectrometry, and next-generation sequencing. Through deep expansion within individual platforms and cross-platform integration, the company continues to strengthen its traditional core businesses while extending into ultra-early disease detection and full-course disease management. This has enabled BioPerfectus to build a broad healthcare ecosystem covering early cancer screening, respiratory infection testing, chronic disease prevention and control, and nutrition management.




Guided by its strategy of sustainable development and global innovation, BioPerfectus is accelerating its international expansion. With subsidiaries in Hong Kong, Indonesia, the United States, and Brazil serving as strategic hubs, the company has established localized operating systems across key markets. Supported by 549 international market access certifications, BioPerfectus products are now available in more than 100 countries and regions worldwide, steadily advancing toward its vision of becoming a world-class precision diagnostics company.

Description
Description

Chairman & CEO Message

Dr. Guoqiang Wang

From the very beginning, BioPerfectus has been committed to contributing to our nation through industry and to bringing benefits to society at large. Over the past decade, our company has concentrated on leading the charge in various disease areas, relentlessly pursuing innovation in diagnostic products, and consistently delivering value to patients, families, and healthcare professionals across the globe. Our active participation in major and emergent public health crises has further solidified our dedication to advancing the healthcare system and safeguarding the health of communities worldwide.



Despite the ongoing global health threats posed by infectious diseases and cancer, we are heartened to observe significant progress in combating these complex diseases, thanks to the collective efforts of medical institutions, industry experts, and multidisciplinary partners. Looking ahead, we are filled with passion and confidence, committing ourselves to be a trusted partner in smart testing and disease management for healthcare professionals. We are determined to address the ongoing diagnostic needs of patients and physicians, to contribute to the achievement of the "Healthy China 2030" strategic goals, and to invest our intelligence and energy in securing a healthier future for humanity.

Contact Us